In a landmark achievement for medical technology, Shanghai-based Neuracle Technology has secured global regulatory precedence with China’s approval of the world’s first implantable brain-machine interface (BMI) system for clinical application. The National Medical Products Administration granted the medical device registration certificate on March 13, 2026, marking a transformative milestone in neurotechnology commercialization.
The pioneering system, designed specifically for quadriplegic patients aged 18-60 with cervical spinal cord injuries, enables thought-controlled hand movement compensation through a minimally invasive implant. The coin-sized device employs extradural electrode placement outside the dura mater, eliminating brain tissue damage while maintaining exceptional signal-to-noise ratio. This surgical approach requires just over an hour for implantation and features wireless power and communication capabilities for long-term use without maintenance interventions.
Clinical trials demonstrated remarkable efficacy across 36 participants, showing 100% improvement in grasping function with some patients exhibiting neural remodeling and additional nerve function recovery. The system translates neural signals into precise digital commands, allowing patients to control specialized gloves for performing essential activities like grasping objects and drinking independently.
Compared to international counterparts, Neuracle’s technology demonstrates superior trauma control, patient compliance, and long-term stability. The company, founded in 2011, anticipates the first clinical application on a patient within the year, potentially revolutionizing rehabilitation for paralyzed individuals worldwide. This breakthrough represents China’s growing leadership in advanced medical technology and sets new standards for the global neurotechnology industry.